These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

932 related articles for article (PubMed ID: 22613337)

  • 1. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
    Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
    Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of Tyrosine Kinase Inhibitors in Japanese Patients with Non-small Cell Lung Cancer Harboring Minor Epidermal Growth Factor Receptor Mutations: Results from a Multicenter Retrospective Study (HANSHIN Oncology Group 0212).
    Otsuka T; Mori M; Yano Y; Uchida J; Nishino K; Kaji R; Hata A; Hattori Y; Urata Y; Kaneda T; Tachihara M; Imamura F; Katakami N; Negoro S; Morita S; Yokota S
    Anticancer Res; 2015 Jul; 35(7):3885-91. PubMed ID: 26124334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of clinical outcomes following gefitinib and erlotinib treatment in non-small-cell lung cancer patients harboring an epidermal growth factor receptor mutation in either exon 19 or 21.
    Lim SH; Lee JY; Sun JM; Ahn JS; Park K; Ahn MJ
    J Thorac Oncol; 2014 Apr; 9(4):506-11. PubMed ID: 24736073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.
    Watanabe S; Tanaka J; Ota T; Kondo R; Tanaka H; Kagamu H; Ichikawa K; Koshio J; Baba J; Miyabayashi T; Narita I; Yoshizawa H
    BMC Cancer; 2011 Jan; 11():1. PubMed ID: 21194487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
    Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
    Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The different efficacy of gefitinib or erlotinib according to epidermal growth factor receptor exon 19 and exon 21 mutations in Korean non-small cell lung cancer patients.
    Sun JM; Won YW; Kim ST; Kim JH; Choi YL; Lee J; Park YH; Ahn JS; Park K; Ahn MJ
    J Cancer Res Clin Oncol; 2011 Apr; 137(4):687-94. PubMed ID: 20552223
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
    Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
    Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The cost-effectiveness analysis of gefitinib or erlotinib in the treatment of advanced EGFR mutant non-small cell lung cancer patients].
    Ma Y; Huang Y; Zhao H; Liu J; Chen L; Wu H; Zhou N
    Zhongguo Fei Ai Za Zhi; 2013 Apr; 16(4):203-10. PubMed ID: 23601301
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lifestyle risks exposure and response predictor of gefitinib in patients with non-small cell lung cancer.
    Ying H; Yang XD; Sun Z; Ning X; Wang Y; Bai C; Chen S; Wang Y
    Med Oncol; 2014 Oct; 31(10):220. PubMed ID: 25216867
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors.
    Chang LC; Lim CK; Chang LY; Chen KY; Shih JY; Yu CJ
    Eur J Cancer; 2019 Sep; 119():77-86. PubMed ID: 31425965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment decisions, clinical outcomes, and pharmacoeconomics in the treatment of patients with EGFR mutated stage III/IV NSCLC in Germany: an observational study.
    Schuette W; Schirmacher P; Eberhardt WEE; Dietel M; Zirrgiebel U; Muehlenhoff L; Thomas M
    BMC Cancer; 2018 Feb; 18(1):135. PubMed ID: 29402243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.
    Heon S; Yeap BY; Lindeman NI; Joshi VA; Butaney M; Britt GJ; Costa DB; Rabin MS; Jackman DM; Johnson BE
    Clin Cancer Res; 2012 Aug; 18(16):4406-14. PubMed ID: 22733536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical impact of switching to a second EGFR-TKI after a severe AE related to a first EGFR-TKI in EGFR-mutated NSCLC.
    Takeda M; Okamoto I; Tsurutani J; Oiso N; Kawada A; Nakagawa K
    Jpn J Clin Oncol; 2012 Jun; 42(6):528-33. PubMed ID: 22457323
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
    Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
    N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [How to make the choice in the retreatment of EGFR-TKI for advanced NSCLC patients who benefited from prior gefitinib therapy: the original drug or switching to a second EGFR-TKI?].
    Tang C; Li X; Guo W; Li J; Qin H; Wang W; Qu L; An J; Gao H; Liu X
    Zhongguo Fei Ai Za Zhi; 2013 Jul; 16(7):345-52. PubMed ID: 23866664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.
    Zhou C; Wu YL; Chen G; Feng J; Liu XQ; Wang C; Zhang S; Wang J; Zhou S; Ren S; Lu S; Zhang L; Hu C; Hu C; Luo Y; Chen L; Ye M; Huang J; Zhi X; Zhang Y; Xiu Q; Ma J; Zhang L; You C
    Lancet Oncol; 2011 Aug; 12(8):735-42. PubMed ID: 21783417
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
    Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
    Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary resistance to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in patients with non-small-cell lung cancer harboring TKI-sensitive EGFR mutations: an exploratory study.
    Lee JK; Shin JY; Kim S; Lee S; Park C; Kim JY; Koh Y; Keam B; Min HS; Kim TM; Jeon YK; Kim DW; Chung DH; Heo DS; Lee SH; Kim JI
    Ann Oncol; 2013 Aug; 24(8):2080-7. PubMed ID: 23559152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase III, randomized, open-label study of ASP8273 versus erlotinib or gefitinib in patients with advanced stage IIIB/IV non-small-cell lung cancer.
    Kelly RJ; Shepherd FA; Krivoshik A; Jie F; Horn L
    Ann Oncol; 2019 Jul; 30(7):1127-1133. PubMed ID: 31070709
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 47.